BR0306715A - Métodos para diagnóstico e tratamento de tumores - Google Patents
Métodos para diagnóstico e tratamento de tumoresInfo
- Publication number
- BR0306715A BR0306715A BR0306715-7A BR0306715A BR0306715A BR 0306715 A BR0306715 A BR 0306715A BR 0306715 A BR0306715 A BR 0306715A BR 0306715 A BR0306715 A BR 0306715A
- Authority
- BR
- Brazil
- Prior art keywords
- diagnosis
- methods
- treatment
- tumors
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"MéTODOS PARA DIAGNóSTICO E TRATAMENTO DE TUMORES". A presente invenção refere-se a novos métodos para o diagnóstico e para o tratamento de tumores, utilizando novos peptídeos para a ligação de radionuclídeos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02000315 | 2002-01-03 | ||
US35870202P | 2002-02-25 | 2002-02-25 | |
PCT/EP2003/000009 WO2003055917A2 (en) | 2002-01-03 | 2003-01-02 | Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0306715A true BR0306715A (pt) | 2004-12-28 |
Family
ID=26077560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0306715-7A BR0306715A (pt) | 2002-01-03 | 2003-01-02 | Métodos para diagnóstico e tratamento de tumores |
Country Status (15)
Country | Link |
---|---|
US (1) | US20040001790A1 (pt) |
EP (2) | EP2239274A1 (pt) |
JP (2) | JP2005523887A (pt) |
CN (1) | CN1612895B (pt) |
AU (1) | AU2003210149B2 (pt) |
BR (1) | BR0306715A (pt) |
CA (1) | CA2468081A1 (pt) |
CY (1) | CY1110923T1 (pt) |
HK (1) | HK1076474A1 (pt) |
IL (2) | IL162201A0 (pt) |
MX (1) | MXPA04006517A (pt) |
NO (1) | NO20043246L (pt) |
PL (1) | PL369371A1 (pt) |
RU (1) | RU2352582C2 (pt) |
WO (1) | WO2003055917A2 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
US20030045681A1 (en) * | 1998-05-11 | 2003-03-06 | Anthony J. Zelano | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
US20030176663A1 (en) * | 1998-05-11 | 2003-09-18 | Eidgenossische Technische Hochscule | Specific binding molecules for scintigraphy |
AU4243201A (en) | 2000-02-24 | 2001-09-03 | Eidgenoess Tech Hochschule | Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis |
BR0113737A (pt) * | 2000-09-07 | 2004-02-25 | Schering Ag | Receptor do domìnio da edbfibronectina (11) |
DK1483297T3 (da) | 2002-03-11 | 2010-05-03 | Philogen Spa | Antistoffer afledt fra anti-ED-B L19 og rettet mod tumorblodkar |
EP1514561A1 (en) * | 2003-09-10 | 2005-03-16 | Philogen S.p.A. | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
DE10348319A1 (de) * | 2003-10-17 | 2005-05-19 | Schering Ag | Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques |
DE602004009169D1 (de) * | 2004-07-22 | 2007-11-08 | Bayer Schering Pharma Ag | Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind |
US20060039863A1 (en) * | 2004-07-22 | 2006-02-23 | Michael Schirner | Use of cyanine dyes for the diagnosis of disease associated with angiogenesis |
US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
ES2291071B1 (es) * | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
EP2015775B1 (en) * | 2006-05-03 | 2011-06-01 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
EP2142567B1 (en) * | 2007-04-02 | 2013-01-16 | Philogen S.p.A. | The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases |
EP2036576A1 (en) * | 2007-09-17 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | ED-B fibronectin as stratification marker for antitumor drugs |
US8253725B2 (en) * | 2007-12-28 | 2012-08-28 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Method and system for generating surface models of geometric structures |
EP2116555A1 (en) | 2008-05-08 | 2009-11-11 | Bayer Schering Pharma Aktiengesellschaft | Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma |
CA2768658C (en) * | 2009-07-22 | 2018-04-03 | Actinium Pharmaceuticals, Inc. | Methods for generating radioimmunoconjugates |
JP5892540B2 (ja) * | 2009-12-25 | 2016-03-23 | 国立研究開発法人理化学研究所 | 生体内にて標的組織に指向する放射標識化合物およびその利用 |
WO2011110490A1 (en) | 2010-03-09 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | Process for the production of radioactively labelled scfv antibody fragments, kits and compositions |
CN104215668A (zh) * | 2014-08-25 | 2014-12-17 | 浙江大学 | 基于theed纤维阵列的二氧化碳传感器及其制备方法 |
US20180340936A1 (en) * | 2015-11-16 | 2018-11-29 | Hefei Lifeon Pharmaceutical Co. Ltd. | Use of ed-b protein in diagnosis of tissue hyperplasia |
CA3040423A1 (en) * | 2016-10-17 | 2018-04-26 | Pfizer Inc. | Anti-edb antibodies and antibody-drug conjugates |
FI4153232T3 (fi) | 2020-05-22 | 2024-09-25 | Philogen Spa | Tnf-a-immunokonjugaattihoito aivokasvainten hoitoon |
US20240342215A1 (en) | 2021-07-14 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3070763B2 (ja) * | 1989-08-09 | 2000-07-31 | ロメッド インコーポレイティド | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 |
ATE503496T1 (de) * | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
TWI259837B (en) * | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
US6171578B1 (en) * | 1999-04-14 | 2001-01-09 | Diatide, Inc. | Benzodiazepine derivatives for imaging thrombi |
CN101073668A (zh) * | 1999-04-28 | 2007-11-21 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
AU4243201A (en) | 2000-02-24 | 2001-09-03 | Eidgenoess Tech Hochschule | Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis |
-
2003
- 2003-01-02 BR BR0306715-7A patent/BR0306715A/pt not_active Application Discontinuation
- 2003-01-02 CA CA002468081A patent/CA2468081A1/en not_active Withdrawn
- 2003-01-02 EP EP10162295A patent/EP2239274A1/en not_active Withdrawn
- 2003-01-02 EP EP03726977A patent/EP1461360B1/en not_active Expired - Lifetime
- 2003-01-02 AU AU2003210149A patent/AU2003210149B2/en not_active Revoked
- 2003-01-02 RU RU2004123785/13A patent/RU2352582C2/ru not_active IP Right Cessation
- 2003-01-02 JP JP2003556447A patent/JP2005523887A/ja not_active Withdrawn
- 2003-01-02 PL PL03369371A patent/PL369371A1/xx unknown
- 2003-01-02 CN CN038019434A patent/CN1612895B/zh not_active Withdrawn - After Issue
- 2003-01-02 WO PCT/EP2003/000009 patent/WO2003055917A2/en active Application Filing
- 2003-01-02 MX MXPA04006517A patent/MXPA04006517A/es active IP Right Grant
- 2003-01-02 IL IL16220103A patent/IL162201A0/xx unknown
- 2003-01-03 US US10/336,041 patent/US20040001790A1/en not_active Abandoned
-
2004
- 2004-05-27 IL IL162201A patent/IL162201A/en not_active IP Right Cessation
- 2004-08-02 NO NO20043246A patent/NO20043246L/no unknown
-
2005
- 2005-09-22 HK HK05108339.8A patent/HK1076474A1/xx not_active IP Right Cessation
-
2009
- 2009-05-29 JP JP2009129965A patent/JP4663020B2/ja not_active Expired - Lifetime
-
2010
- 2010-11-17 CY CY20101101038T patent/CY1110923T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2003055917A2 (en) | 2003-07-10 |
RU2352582C2 (ru) | 2009-04-20 |
IL162201A (en) | 2011-04-28 |
AU2003210149A1 (en) | 2003-07-15 |
AU2003210149B2 (en) | 2008-10-09 |
JP2005523887A (ja) | 2005-08-11 |
RU2004123785A (ru) | 2005-08-10 |
CY1110923T1 (el) | 2015-06-10 |
EP1461360A2 (en) | 2004-09-29 |
US20040001790A1 (en) | 2004-01-01 |
CA2468081A1 (en) | 2003-07-10 |
NO20043246L (no) | 2004-08-02 |
MXPA04006517A (es) | 2005-03-31 |
JP2009209149A (ja) | 2009-09-17 |
PL369371A1 (en) | 2005-04-18 |
CN1612895B (zh) | 2010-05-12 |
EP1461360B1 (en) | 2010-08-18 |
EP2239274A1 (en) | 2010-10-13 |
HK1076474A1 (en) | 2006-01-20 |
WO2003055917A3 (en) | 2003-12-24 |
CN1612895A (zh) | 2005-05-04 |
IL162201A0 (en) | 2005-11-20 |
JP4663020B2 (ja) | 2011-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0306715A (pt) | Métodos para diagnóstico e tratamento de tumores | |
AU2003205077A1 (en) | Imaging agents and methods of imaging naaladase of psma | |
HK1145692A1 (zh) | 人血管生成素- 的特異結合劑 | |
WO2003101401A3 (en) | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer | |
CY1110256T1 (el) | Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου | |
DK2308975T3 (da) | Antistofmolekyler, der har specificitet for human tumor nekrotiserende faktor alfa, og anvendelse deraf | |
DE50310516D1 (de) | Fredericamycin-derivate | |
ATE527552T1 (de) | Mr-darstellungsverfahren zur diskriminierung zwischen gesundem und tumorgewebe | |
ZA200409492B (en) | Compositions and methods for the diagnosis and treatment of tumor. | |
EP1708751A4 (en) | METHOD OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGEN EXPOSED ON APOPTOTIC TUMOR CELLS | |
WO2006021412A3 (en) | Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain | |
HK1052940A1 (en) | Synthetic methods for aplidine and new antitumoralderivatives, methods of making and using them | |
EP1071443A4 (en) | ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE | |
WO2004076614A3 (de) | Humane nukleinsäuresequenzen aus prostatakarzinomen | |
WO2003073818A3 (en) | Proteomic analysis of tumors for development of consultative report of therapeutic options | |
IL207012A0 (en) | Diagnosis and therapy of cancer using sgp28-related molecules | |
ATE403438T1 (de) | Immuntherapeutische kombinationen zur tumorbehandlung | |
WO2004047757A3 (en) | Diagnosing and treating hematopoietic cancers | |
EA200800948A1 (ru) | Биотиндиаминопроизводные и их конъюгаты с макроциклическими хелатирующими реагентами | |
BRPI0415355A (pt) | triarilimidazóis | |
EP1323732A4 (en) | BETA-CATENINE NUCLEAR LOCALIZING PROTEIN | |
UY26170A1 (es) | Antigeno (c42) asociados a tumores | |
DE60301891D1 (de) | Peptid für die Diagnose und Therapie von Tumoren | |
FR2842109B1 (fr) | Utilisation d'un extrait de chrysanthellum | |
ATE328082T1 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B10A | Cessation: cessation confirmed |
Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DA PETICAO NO 020110067152/RJ DE 27.06.2011. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 51/10 (2006.01), A61K 51/08 (2006.01), C07K 1 |